^
Association details:
| Biomarker: | MSH4 L359I |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Complete response to anti-PD-L1 antibody in a metastatic bladder cancer associated with novel MSH4 mutation and microsatellite instability
Published date:
03/30/2020
Excerpt:
We report a complete responder to PD-L1 blockade who had MSH4 mutated metastatic bladder cancer...His disease was primary refractory to first-line platinum-based chemotherapy but attained complete response to second-line atezolizumab. The novel MSH4 L359I mutation is associated with MSI and high mutational burden leading to remarkable response to PD-L1 blockade.